Globus Medical, Inc. Class A Forecast, price target & analysts
Globus Medical, Inc. Class A Target price 2025 - Analyst rating & recommendation
Globus Medical, Inc. Class A Classifications & Recommendation:
Globus Medical, Inc. Class A Price Target
| Target Price | $98.69 |
| Price | $78.67 |
| Potential |
25.45%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Globus Medical, Inc. Class A 2026 .
The average Globus Medical, Inc. Class A target price is $98.69.
This is
25.45%
register free of charge
$115.00
46.18%
register free of charge
$90.00
14.40%
register free of charge
|
|
| A rating was issued by 17 analysts: 11 Analysts recommend Globus Medical, Inc. Class A to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Globus Medical, Inc. Class A stock has an average upside potential 2026 of
25.45%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.52 | 2.68 |
| 60.62% | 6.43% | |
| EBITDA Margin | 19.30% | 32.61% |
| 12.64% | 68.93% | |
| Net Margin | 4.09% | 15.52% |
| 56.36% | 279.38% |
14 Analysts have issued a sales forecast Globus Medical, Inc. Class A 2025 . The average Globus Medical, Inc. Class A sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Globus Medical, Inc. Class A EBITDA forecast 2025. The average Globus Medical, Inc. Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Globus Medical, Inc. Class A Analysts have issued a net profit forecast 2025. The average Globus Medical, Inc. Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.75 | 3.03 |
| 29.91% | 304.00% | |
| P/E | 25.99 | |
| EV/Sales | 3.86 |
8 Analysts have issued a Globus Medical, Inc. Class A forecast for earnings per share. The average Globus Medical, Inc. Class A <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Globus Medical, Inc. Class A stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Globus Medical, Inc. Class A...
Current Globus Medical, Inc. Class A Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays | Locked ➜ Locked | Locked | Feb 24 2025 |
| Citizens Capital Markets | Locked ➜ Locked | Locked | Feb 24 2025 |
| Wells Fargo | Locked ➜ Locked | Locked | Feb 21 2025 |
| Stifel | Locked ➜ Locked | Locked | Feb 21 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 21 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 06 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Jan 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Citizens Capital Markets: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Stifel: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 06 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Jan 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
